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Abstract 
Although ferrocene derivatives have attracted considerable attention as possible anticancer agents, the 
medicinal potential of diiron complexes has remained largely unexplored. Herein, we describe the 
straightforward multigram-scale synthesis and the antiproliferative activity of a series of diiron 
cyclopentadienyl complexes containing bridging vinyliminium ligands. IC50 values in the low to mid-
micromolar range were determined against cisplatin sensitive and resistant human ovarian carcinoma 
(A2780 and A2780cisR) cell lines. Notable selectivity towards the cancerous cells lines compared to 
the non-tumoural human embryonic kidney (HEK-293) cell line was observed for selected compounds. 
The activity seems to be multimodal, involving ROS generation and, in some cases, a fragmentation 
process to afford monoiron derivatives. The large structural variability, amphiphilic character and good 
stability in aqueous media of the diiron vinyliminium complexes collectively provide favourable 
properties compared to other widely studied classes of iron-based anticancer candidates.  
 
Keywords: bioorganometallic chemistry, metal-based drugs, diiron complexes, vinyliminium ligand, 
cytotoxicity. 
 
Introduction 
The peculiar characteristics of transition metals, including the variety of accessible redox states and 
coordination sites, offer a degree of structural diversity to metal-based drugs that is inaccessible to 
organic molecules.1 Cisplatin and its derivatives are currently employed in the first line treatment of a 
wide range of cancers, but despite their unquestionable efficacy, severe side effects and progressive 
acquisition of drug resistance are associated with their use.2,3 Consequently, a substantial effort has 
been focused on the development of alternative metal-based anticancer drugs with the ability to 
overcome the limitations of platinum-based chemotherapics.4 In addition to alternative platinum-based 
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pharmaceuticals with enhanced properties,5 complexes containing, among the others, titanium,6 
ruthenium,7 gold 8 and iridium 8e,9 ions have been explored. However, several of the proposed 
compounds exhibit undesirable features such as low stability leading to the rapid substitution of ligands 
and poor water solubility. Indeed, stability in physiological media within a reasonable timeframe and 
an appropriate balance between water solubility and lipophilicity,10 the latter favouring tumour tissue 
penetration and cellular uptake,11 are important factors. In some cases, limited ligand exchange, e.g. 
where chloride ligands are replaced by water molecules, is key to the activation of the drug.12 Instead, 
extensive degradation of a complex in biological medium could lead to fragments or aggregates which 
lack a clear pharmacological role.13 The titanium complexes budotitane and titanocene dichloride failed 
clinical trials for reasons that are imputable to these drawbacks,6b while the ruthenium(III) complex 
KP1019 7a and the platinum(II) complex cis-dichlorobis(cyclopentylamine)platinum(II)14 were limited 
by their poor water solubility. 
As a bio-essential, relatively non-toxic element for which transport and storage mechanisms exist, iron 
is an appealing element for a metal-based drug.15 Several monoiron complexes, including iron(II) 
cyclopentadienyl complexes,16  have been investigated for their anticancer behaviour, and 
functionalized ferrocenes have emerged as promising candidates.17,18 For example, a series of 
ferrocifens, constituted by the ferrocene unit bearing hydroxytamoxifen-type substituents on one of the 
two cyclopentadienyl rings, display significant cytotoxicity against a panel of cancer cell lines, which 
was attributed to a synergic effect between the organic moiety and the iron centre.19a The redox 
chemistry of the Fe(II) centre is believed to be an influential factor in the cytotoxicity of these 
compounds, as the oxidation to Fe(III) inside the cancer cell generates reactive metabolites and triggers 
the production of toxic substances.19b,20 However, ferrocifens usually possess insufficient water 
solubility and consequently must be carefully formulated for potential clinical applications.21  
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The anticancer properties of diiron complexes are substantially unexplored, despite the opportunity of 
cooperative effects between the two metal centres and multisite coordination modes available to the 
ligands.22 Hence, reactivity patterns that are not viable for mononuclear species may be accessible with 
dinuclear complexes giving rise to diverse structural motifs and physico-chemical properties.23 It is 
worth mentioning that nature selected diiron carbonyl units as the catalytic core of some highly 
efficient enzymes.24 
Fe2Cp2(CO)4 (Cp = C5H5) is a classical starting compound in organometallic synthesis, enabling the 
preparation of unusual molecular architectures through sequential regio- and stereo-selective 
reactions.25 Herein, we report a series of diiron complexes with a bridging vinyliminium ligand as a 
novel family of cytotoxic organometallic compounds (Figure 1). The complexes can be obtained on 
gram scales from Fe2Cp2(CO)4 via the stepwise assembly of isocyanide and alkyne units,
25a and display 
acceptable water solubility and stability. Spectro-electrochemical studies, ROS analysis and 
investigations on the interaction with biomolecules have been conducted to ascertain a possible mode 
of action. 
 
Figure 1. General structure of diiron µ-vinyliminium complexes obtained from the assembly of one isocyanide 
(fragment in red colour) and one alkyne (fragment in blue colour), starting from Fe2Cp2(CO)4. 
 
Results and discussion 
1. Synthesis and characterization of compounds 
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The vinyliminium complexes [2-19]CF3SO3 were prepared from Fe2Cp2(CO)4 following a four-step 
procedure (Scheme 1). The aminocarbyne precursors [1a-c]CF3SO3 were obtained via carbon 
monoxide/isocyanide substitution and subsequent alkylation in near quantitative yields (Scheme 1, 
steps 1-2).26 One carbonyl ligand is subsequently replaced by a more labile acetonitrile molecule, 
which allows the entry and insertion of the alkyne into the iron-carbyne bond, forming the 
vinyliminium ligand (Scheme 1, steps 3-4). The last two steps were conducted using optimised 
literature procedures.27 The alkyne insertion reaction (step 4) is tolerant of various hetero-functional 
groups, e.g. thiophenyl and pyridyl, despite their affinity for iron coordination:28 the resulting 
vinyliminium ligands are reported here for the first time. The final complexes [2-19]CF3SO3, 
synthesised at ambient temperature and purified via chromatography without the need of an inert 
atmosphere, were isolated in good to high yields (52-96%) as air stable solid materials. Concerning the 
choice of the counteranion, it should be noted that a variety of ionic metal complexes with triflate as 
counteranion have been proposed to date as possible anticancer drugs,29 and, among them, Ru(II) arene 
complexes with bidentate N,N-ligands were investigated in vivo showing no significant toxicity.29b 
C
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1) CNR, MeCN
Fe2Cp2(CO)4
+
2) MeCF3SO3, CH2Cl2
Fe Fe
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4) R'C CR'', CH2Cl2
 
 R   R R' R'' 
[1a]+ Me  [2]+ Me Ph H 
[1b]+ Xyl = 2,6-C6H3Me2  [3]
+
 Me 2-naphthyl H 
[1c]+ CH2Ph  [4]
+
 Me 3-C6H4OH H 
   [5]+ Me 4-C6H4CO2H H 
   [6]+ Me 3-thiophenyl H 
   [7]+ Me Me H 
   [8]+ Me CO2Me CO2Me 
   [9]+ Me Me Me 
   [10]+ Me Ph Ph 
   [11]+ Xyl Ph H 
   [12]+ Xyl Me H 
   [13]+ Xyl CH2OH H 
   [14]+ Xyl 3-thiophenyl H 
   [15]+ Xyl 2-naphthyl H 
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   [16]+ Xyl 2-pyridyl H 
   [17]+ Xyl CO2Me CO2Me 
   [18]+ Xyl Me Me 
   [19]+ CH2Ph Ph H 
 
Scheme 1. Synthesis of diiron µ-vinyliminium complexes (with CF3SO3
− as the counteranion). 
 
Compounds [7-13]CF3SO3 and [17-18]CF3SO3 were reported previously,
27 whereas [1-6]CF3SO3, [14-
16]CF3SO3 and [19]CF3SO3 are unprecedented. [18]CF3SO3 was primarily obtained in its trans form 
(with respect to the geometry of the Cp ligands),30 before being quantitatively converted into the 
thermodynamically stable cis product upon gentle heating in methanol. The new products were 
characterized by IR, NMR (Figures S1-S37) and UV-Vis spectroscopy. The IR spectra, recorded in 
dichloromethane, display two intense absorptions related to the terminal and the bridging carbonyl 
ligands (e.g. at 1988 and 1809 cm−1 in [3]+), as well as a band corresponding to the vibration of the 
[NC1C2] group in the range of 1662-1687 cm−1 ([2-10]+ and [19]+) and 1610-1632 cm−1 ([11-18]+). The 
1H and 13C NMR spectra of [2-10]CF3SO3 exhibit a single set of resonances, whereas E-Z isomerism 
due to the two possible orientations of the different N-substituents should in principle concern [11-
19]CF3SO3. In [19]CF3SO3, containing N-substituents with comparable steric hindrance (i.e., methyl 
and benzyl), the E/Z ratio is ca. 3:2. Compounds [11-18]CF3SO3 comprise the encumbered xylyl group, 
and [12]CF3SO3 in particular exists exclusively in the E form; the same E orientation is prevalent in 
[11,13-16]CF3SO3 (E/Z ratio ranges from 4 to 9). Conversely [17-18]CF3SO3, bearing a C
2-substituent 
(R′′), are found in the Z conformation, whereby the xylyl group points away from R′′. The most salient 
NMR features are represented by the resonances of the C1 and C3 carbons, found between 218-233 ppm 
and 171-208 ppm, in agreement with their amino-alkylidene 31 and alkylidene nature,32 respectively. 
The 19F NMR spectra of [2-19]CF3SO3 (in D2O) exhibit the singlet related to the triflate anion at ca. -
79 ppm. 
The X-ray structures of [10]CF3SO3, [14]CF3SO3·0.5CH2Cl2, [15]CF3SO3·CH2Cl2 and 
[16]CF3SO3·0.5CH2Cl2 were determined; a view of the cation [10]
+ is depicted in Figure 2, while the 
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other structures are shown in the Supporting Information together with a selection of geometric 
parameters (Figures S38-S40, Table S1). The organometallic cations are composed of a 
[Fe2Cp2(CO)(µ-CO)] skeleton, with the Cp-ligands in a cis-geometry, and a [µ-η
1:η3-
C3(R′)C2HC1N(Me)(Xyl)]+ vinyliminium ligand. The bridging alkylidene C3 carbon is slightly 
asymmetric respect to the Fe centres, for instance in [14]+ Fe(2)-C(3) and Fe(1)-C(3) distances are 
2.048(8) and 1.971(8) Å, respectively. The C(1)-N(1) distances are 1.284(3), 1.293(10), 1.313(12) and 
1.294(12) Å in [10]+, [14]
+
, [15]
+ and [16]+, respectively, in accordance with the iminium character; 
however, the Fe(2)-C(1) distances [1.842(2), 1.844(7), 1.832(11) and 1.852(3) Å in [10]+, [14]
+
, [15]
+ 
and [16]+, respectively] are indicative of some aminoalkylidene nature.31c,33 The iminium moiety 
displays an E-conformation that has been consistently detected by NMR spectroscopy (see above). 
 
 
Figure 2. View of the structure of [Fe2Cp2(CO)(µ-CO){µ-η
1:η3-C3(Ph)C2(Ph)C1NMe2}]
+, [10]+. Displacement 
ellipsoids are at the 30% probability level. 
 
2. Solubility and stability in aqueous media 
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Compounds [2-19]CF3SO3 possess amphiphilic character, being soluble in organic solvents such as 
dichloromethane and acetone as well as having appreciable solubility in water. The water solubility of 
[2-19]CF3SO3 was assessed at 21 °C in saturated D2O solutions, monitored by 
1H NMR spectroscopy 
(Table 1).34,35 The resulting solubility values fall within the range of 4.8·10-4 – 9.8·10-3 mol·L-1 (0.33 – 
5.4 g·L-1) and are comparable to some platinum-based drugs.36,37 The presence of a Me substituent in 
place of a Xyl group on the iminium moiety generally leads to a two- to four-fold increase in water 
solubility (compare solubility ratios for Me/Xyl analogues [2]+/[11]+, [3]+/[15]+, [6]+/[14]+, [8]+/[17]+ 
and [9]+/[18]+), and [4]CF3SO3, [7]CF3SO3 and [8]CF3SO3 reach the highest values (∼10
−2 mol·L-1). 
Interestingly, the Z isomers of [11,14-16] are prevalent in saturated D2O solutions, whereas the E/Z 
ratio of these compounds in DMSO or acetone is >>1.  
Octanol-water partition coefficients (Log Pow, see Table 1) of [2-19]CF3SO3 were assessed 
spectrophotometrically using the shake-flask method (see Experimental for details).34b The majority of 
compounds displays an amphiphilic character (−0.5 < Log Pow < 0.5), with the dimethyl-iminium 
derivatives [2-10]CF3SO3 being more hydrophilic than the N-Xyl complexes [11-18]CF3SO3. 
Table 1. Solubility in D2O (based on 
1H NMR spectroscopy, using Me2SO2 as an internal standard) and octanol-
water partition coefficients (Log Pow) of diiron complexes (all data refer to T = 21 °C). 
 
Compound Solubility in D2O / molL
−1 Solubility in D2O / gL
−1 Log Pow 
[2]CF3SO3 3.910−3 2.4 –0.2 
[3]CF3SO3 1.810−3 1.2 0.2 
[4]CF3SO3 1.410−2 8.7 –0.34 
[5]CF3SO3 3.910−3 2.5 –0.6 
[6]CF3SO3 3.510−3 2.1 –0.12 
[7]CF3SO3 1.410−2 7.6 –0.3  
[8]CF3SO3 1.910−2 12 –1.0 
[9]CF3SO3 7.510−3 4.2 –1.2 
[10]CF3SO3 4.310−4 0.29 0.9 
[11]CF3SO3 9.410−4 0.65 0.4 
[12]CF3SO3 1.010−3 0.63 0.0 
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[13]CF3SO3 1.010−3 0.65 –0.1 
[14]CF3SO3 1.010−3 0.70 0.5 
[15]CF3SO3 7.910−4 0.59 1.4 
[16]CF3SO3 1.710−3 1.2 0.1  
[17]CF3SO3 5.310−3 3.9 –0.6 
[18]CF3SO3 2.010−3 1.3 0.0 
[19]CF3SO3 4.610−3 3.1 0.2 
 
The stability of [2-19]CF3SO3 in D2O or DMSO-d6/D2O solution was checked by 
1H NMR after 72 
hours at 37 °C, these conditions resembling those of the cytotoxicity assays. A single set of signals was 
observed in the spectra of freshly-prepared solutions, attributed to the starting materials (two sets of 
signals in case of E/Z isomerism). No significant variation was observed by 1H NMR after 72 hours, 
while a small amount of an orange-brown precipitate was noticed. In one case, the precipitate was 
isolated and identified as iron(III) oxide (haematite) by Raman analysis (see Experimental). It is 
presumable that slow, partial degradation in water liberates Fe2+ ions, then converted into Fe2O3. 
Substantial stability of [2-19]CF3SO3 was also observed in the presence of 0.1 M NaCl (D2O or 
DMSO-d6/D2O solution).  
The stability of [2-19]CF3SO3 in RPMI-1640 cell culture medium was monitored using IR 
spectroscopy and mass spectrometry and, with the exception of [8]CF3SO3 and [17]CF3SO3 which 
undergo extensive decomposition, the complexes showed good stability. It is possible that the observed 
degradation of [8]CF3SO3 and [17]CF3SO3 in cell culture medium is related to the presence of two 
CO2Me substituents on the vinyliminium frame, that is known to favour nucleophilic additions to C
1.38 
 
3. Spectro-electrochemical studies and reduction behaviour 
The electrochemistry of selected complexes, i.e. [7-9]CF3SO3, [11]CF3SO3 and [17-18]CF3SO3, was 
investigated in both organic and aqueous solvents. In general, the investigated complexes showed CV 
profiles in THF/[NnBu4]PF6 or CH2Cl2/[N
nBu4]PF6 involving a chemically reversible oxidation and two 
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reduction processes, complicated by subsequent chemical reactions (see Table 2 and Figures S41-S43). 
These findings are in accordance with the previous studies on [Fe2Cp2(CO)(µ-CO){µ-η
1:η3-
C3(Et)C2HC1N(Me)(Xyl)}]CF3SO3, [20]CF3SO3.
39
 
 
Table 2. Formal electrode potential (V vs. FeCp2) and peak-to-peak separations (mV) for redox processes in 
THF/[NnBu4]PF6 0.2 M. 
 Reduction Oxidation 
 E°’1 ∆E1
a 
E°’2 ∆E2
a
 E°’3 ∆E3
a
 
[7]CF3SO3
 
==  −1.45 140 +0.55 90 
[8]CF3SO3
 
−2.00b  −1.15 117 +0.88b  
[9]CF3SO3
 d ==  −1.49b  +0.62 95 
[11]CF3SO3
 −1.41 140 −1.30b  +0.66 110 
[17]CF3SO3
 
−2.01b  −1.06 110 +0.97b  
[18]CF3SO3
 d 
==  −1.41c 90 +0.70 90 
[20]CF3SO3 
39 
−1.48 95 −1.31 120 +0.62 92 
a Measured at 0.1 V s-1. b Peak potential value for irreversible processes. c Partially chemically reversible 
process. d In CH2Cl2/[N
nBu4]PF6 0.2 M. 
 
In a phosphate buffer solution (pH = 7.3), [2,7,11,12]CF3SO3 exhibit two chemically irreversible 
oxidations, falling in between +0.56 and +1.21 V (vs FeCp2), whereas [8,9,17,18]CF3SO3 possess a 
single oxidation in the same range. These oxidations led to the deposition of degradation products on 
the surface of the carbon glassy working electrode. During the cathodic scan, one reduction peak was 
observed between −0.87 and −1.20 V (Table 3). In the reverse scan, an intense re-oxidation peak 
indicated accumulation of the electro-generated species on the electrode surface during the reduction 
step (Figure S44).  
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Table 3. Electrode potentials (V vs. FeCp2 and in brackets vs. NHE) for redox processes of selected compounds 
in phosphate buffer solution at a carbon glassy electrode. 
 Reduction a Oxidation a 
Compound Epc 
Epa  
(return peak) 
Epa1 Epa2 
[2]CF3SO3 −1.12 
(−0.71) 
−0.40 
(+0.01) 
+0.61 
 (+1.02) 
+0.86 
 (+1.27) 
[7]CF3SO3 −1.14 
(−0.73) 
−0.49 
(−0.08) 
+0.71 
(+1.12) 
+1.02 
(+1.43) 
[8]CF3SO3 −0.99 
(−0.58) 
+0.10 
(+0.51) 
+0.87 
(+1.28) 
n.d. 
[9]CF3SO3 −1.20 
(−0.79) 
−0.58 
(−0.17) 
+0.65 
(+1.06) 
n.d. 
[11]CF3SO3 −0.98 
(−0.57) 
−0.56 
(−0.15) 
+0.56 
(+0.97) 
+0.97 
(+1.38) 
[12]CF3SO3 −0.92 
(−0.51) 
−0.46 
(-0.05) 
+0.71 
(+1.12) 
+1.21 
(+1.62) 
[17]CF3SO3 −0.87 
(−0.46) 
−0.26 
(+0.15) 
+1.04 
(+1.45) 
n.d. 
[18]CF3SO3 −1.16 
(−0.75) 
−0.36 
(+0.05) 
+0.66 
(+1.07) 
n.d. 
a Cathodic (Epc) and anodic (Epa) peak potentials measured at 0.1 V s
-1; n.d. = not detected. 
 
The oxidation of [2, 7-9, 11, 12, 7, 18]CF3SO3 in phosphate buffer solution (pH = 7.3) occurs at 
potentials of Epa > +0.95 V, which exceed those available in a biological environment where O2 is the 
strongest oxidant (E° = +0.816 V vs NHE). The reduction potentials, however, range from -0.79 V for 
[9]CF3SO3 to -0.46 V for [17]CF3SO3, and the less negative values reach the biologically relevant 
range of potentials.34b,40 
We recently demonstrated that the one-electron reduction of [20]CF3SO3 in THF solution triggers a 
cascade reaction leading to the formation of the iron(II) vinyl-aminoalkylidene complex 21a, 
cyclopentadiene and atomic iron (Scheme 2). A similar response was observed for [13]CF3SO3, which 
converts into 21b upon reaction with CoCp2 (Scheme 2). Previously, compounds similar to 21a-b (R = 
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Me or Xyl; R′ = alkyl or CO2Me; R′ = H, alkyl or CO2Me) were obtained by treatment of diiron 
vinyliminium precursors with sodium hydride41 or, unexpectedly, tetrabutylammonium cyanide.42 
 
Scheme 2. Synthesis of Fe(II)-vinyl-aminoalkylidene complexes promoted by reduction of Fe(II)-Fe(II)-
vinyliminium precursors, via Fe(0) elimination. Red pathway: mechanism proposed for the conversion of [20]+ to 
21a on the basis of NMR, electrochemical, magnetometric and DFT studies.39 
 
In order to determine whether the fragmentation reaction, leading to the production of 21a-b, could be 
extended to compounds containing a R′ = aryl group, the reduction behaviour of [11]CF3SO3 was 
studied. The reaction of [11]CF3SO3
 with CoCp2 in anhydrous THF afforded 
[FeCp(CO){C1N(Me)(Xyl)C2HC3(Ph)C(=O)}], 21c, in high yield (Scheme 2). Compound 21c was 
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fully characterized by analytical as well as spectroscopic methods, and its structure was confirmed by 
single crystal X-ray diffraction. The IR spectrum (in CH2Cl2) displays absorptions related to the 
carbonyl ligand, the acyl group and the aminocarbene-nitrogen bond at 1919, 1612 and 1571 cm−1, 
respectively. The 1H NMR spectrum (in acetone-d6) consists of one set of resonances with the C
2H 
proton, occurring at 6.96 ppm, reflecting the alkenic nature of the C2=C3 interaction. The 13C NMR 
spectrum shows the resonance of the C1 carbon at 265 ppm which is in alignment with the 
aminoalkylidene character. The X-ray structure of 21c (Figure 3) resembles that previously reported for 
21a, with the substituents around the partially double C1-N bond arranged in the E configuration.39   
 
 
Figure 3. Molecular structure of [FeCp(CO){η2-C1Me(Xyl)C2HC3(Ph)C(=O)}], 21c. Displacement ellipsoids are at 
the 30% probability level. H-atoms have been omitted for clarity. Selected bond lengths (Å) and angles (°): 
Fe(1)−C(7) 1.923(5), Fe(1)−C(10) 1.911(4), Fe(1)−C(6) 1.737(6), C(7)−C(8) 1.536(6), C(8)−C(9) 1.325(5), C(9)-
−C(10) 1.459(5), C(10)−N(1) 1.325(5), C(6)−O(1) 1.129(5), C(7)−O(2) 1.211(5), C(7)−Fe(1)−C(10) 83.13(18), 
Fe(1)−C(7)−C(8) 113.5(3), C(7)−C(8)−C(9) 111.7(4), C(8)−C(9)−C(10) 116.3(4), C(9)−C(10)−Fe(1) 114.6(3), 
Fe(1)−C(6)−O(1) 178.3(5). 
 
A spectro-electrochemical investigation on [11]CF3SO3 in THF/[N
nBu4]PF6 suggested that the 
formation of 21c follows a pathway similar to the conversion of [20]+ to 21a (Scheme 2). Indeed, when 
the working electrode potential was slowly cycled between 0.0 and −1.7 V (scan rate 2 mV s-1), the IR 
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absorptions of [11]+ (1992, 1815, 1631, 1587 cm-1) were initially replaced by new bands at 1951, 1594 
and 1556 cm-1 (Figure S45A), corresponding to a ferra-ferrocene intermediate (INT, Scheme 2), where 
only one carbonyl ligand remains (Figure S45B). A residual, weak band at 1774 cm-1 might be due to 
traces of the unstable dinuclear radical species 11. Bands at 1890, 1696, 1602 and 1591 cm-1 appeared 
at lower potentials, corresponding to [INT]−. The bands of [11]+ returned, together with a weak 
absorption at 1920 cm-1 related to 21c, at the end of the return scan when the initial potential was 
reinstated (Figure S46).  
Repeating the spectro-electrochemical study in a 0.2 M solution of H2O in THF, no significant change 
was observed.43 This outcome suggests that the production of 21c from [11]CF3SO3 could be 
reproducible in an aqueous environment. 
A cyclic voltammetry study on 21c evidenced one accessible mono-electron oxidation (E°′ = −0.09 V, 
∆Ep = 66 mV) and one mono-electron reduction (E°′ = −1.87 V, ∆Ep = 78 mV), both diffusion 
controlled and electrochemically and chemically reversible in the time scale of the experiment (Figure 
S47). In addition, in situ IR spectro-electrochemical analyses enabled the spectroscopic 
characterization of the oxidized and reduced products, [21c]+ and [21c]− (Figure S48). The IR 
absorption of the carbonyl ligand was detected at 2025 cm−1 for [21c]+ and at 1854 cm−1 for [21c]− (see 
Table S2 for details). 
 
4. Cytotoxicity studies and assessment of ROS production 
The cytotoxicity of [2-19]CF3SO3, 21b and 21c was assessed against cisplatin sensitive and cisplatin 
resistant human ovarian carcinoma (A2780 and A2780cisR) cell lines and the non-tumoural human 
embryonic kidney (HEK-293) cell line (Table 4). The cytotoxicity ranges from inactive (IC50 > 200 
µM) to the nanomolar range. In general, the IC50 values of the diiron complexes correlate to the 
experimental Log Pow values, i.e. with the cytotoxicity increasing with increasing lipophilicity. 
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Compounds [11]CF3SO3 (R = Xyl, R′ = Ph, R′′ = H), [15]CF3SO3 (R = Xyl, R′ = 2-naphthyl, R′′ = H) 
and [18]CF3SO3 (R = Xyl, R′ = Me, R′′ = Me) are the most active against the A2780 cell line. On the 
other hand, [5]CF3SO3 (R = Me, R′ = 4-C6H4OH, R′′ = H) and [8]CF3SO3 (R = Me, R′ = CO2Me, R′′ = 
CO2Me) are inactive against all tested cell lines with IC50 values > 200 µM. Complexes [3,10-16,18-
19]CF3SO3 all overcome cisplatin resistance in the A2780cisR cell line, with [11]CF3SO3 and 
[15]CF3SO3 possessing the lowest IC50 of 1.2 ± 0.2 µM compared to 26 ± 3 µM for cisplatin. A 
significant selectivity (S.I. values, Table 4) towards the A2780 cell line is observed compared to the 
non-tumoural HEK-293 cell line for [1-2,7,10-11,16,18-19]CF3SO3; in particular, [10]CF3SO3, 
presenting low micromolar cytotoxicity against the A2780 cells, exhibits nearly seven-fold selectivity. 
Interestingly, the benzyl compound [19]CF3SO3 afforded comparable IC50 values against A2780 and 
A2780cisR, and almost five-fold selectivity towards the cisplatin resistant cell line vs. the non tumoural 
cell line.   
Complex 21c, derived from [11]+, is cytotoxic against A2780 and A2780cisR cell lines, and has 
impressive selectivity (>12-fold) with respect to the HEK-293 cell line. On the other hand, 21b, derived 
from [13]+, is essentially non cytotoxic. 
 
Table 4. IC50 values (µM) determined for compounds [2-19]CF3SO3, 21b, 21c and cisplatin on human ovarian 
carcinoma (A2780), human ovarian carcinoma cisplatin resistant (A2780CisR) and human embryonic kidney 
(HEK-293) cell lines after 72 hours exposure. Values are given as the mean ± SD. Selectivity indexes (S.I.) 
calculated as ratio between IC50 values related to HEK-293 and A2780 cell lines. 
 
 
Compound. A2780 A2780cisR HEK-293 S.I. 
[2]CF3SO3 15 ± 2 72 ± 5 61 ± 4 4.1 
[3]CF3SO3 2.9 ± 0.2 9.3 ± 0.7 12.0 ± 0.7 4.1 
[4]CF3SO3 163 ± 16 172 ± 11 200 ± 21 1.2 
[5]CF3SO3 > 200 > 200 > 200 == 
[6]CF3SO3 30 ± 2 60 ± 4 33 ± 4 1.1 
[7]CF3SO3 35 ± 3             86 ± 7               > 200 > 5.7 
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[8]CF3SO3 > 200 > 200 > 200 == 
[9]CF3SO3 55 ± 3 107 ± 9 158 ± 12 2.9 
[10]CF3SO3 1.8 ± 0.2 7.5 ± 0.3 12 ± 1 6.7 
[11]CF3SO3 0.50 ± 0.06   1.2 ± 0.2             2.4 ± 0.2 4.8 
[12]CF3SO3 2.7 ± 0.4 3.5 ± 0.6 2.2 ± 0.3 0.8 
[13]CF3SO3 11.6 ± 0.6 21 ± 2 13.4 ± 1.0 1.2 
[14]CF3SO3 2.1 ± 0.5 2.9 ± 0.3 2.2 ± 0.4 1.0 
[15]CF3SO3 0.40 ± 0.06 1.2 ± 0.2 1.4 ± 0.1 3.5 
[16]CF3SO3 1.4 ± 0.2 3.6 ± 0.1 5.8 ± 0.4 4.1 
[17]CF3SO3 17.0 ± 0.8 35 ± 7 21.7 ± 1.4 1.3 
[18]CF3SO3 0.90 ± 0.06 4.0 ± 0.3 5.0 ± 0.4 5.6 
[19]CF3SO3 2.4 ± 0.3 2.8 ± 0.2 11.6 ± 0.4 4.8 
21b 180 ± 1 > 200 > 200 == 
21c 16 ± 2             26 ± 3               > 200 > 12 
cisplatin 2.7 ± 0.1 26 ± 3 10.0 ± 0.7 3.7 
 
 
Intracellular ROS production, induced by a selection of complexes, was monitored by fluorescence 
measurements using the DCFH-DA assay. A2780 and A2780cisR cells were continuously exposed to 
[7]CF3SO3, [11]CF3SO3, [12]CF3SO3, [18]CF3SO3, 21b, 21c, cisplatin (as a reference compound) and 
H2O2 (as a positive control). Appreciable intracellular ROS levels were observed after ca. 20 hours of 
treatment and progressively increased up to 24 hours (Figure 4). In particular, [11]CF3SO3 elicited a 
ROS production in A2780 cells close to that recorded for H2O2, whereas ROS formation triggered by 
exposure to 21b and 21c was considerably higher than the positive control (H2O2) in both A2780 and 
A2780cisR cell lines. The ROS level detected in the A2780 cell line treated with 21c is significantly 
higher than that elicited by 21b. 
 
 
17 
 
 
 
Figure 4. Fluorescence kinetics measurements of intracellular reactive oxygen species (ROS). (A) A2780 and 
(B) A2780cisR cells incubated for 24 hours with 100 µM of iron compounds at 37 °C. N.B.: values marked with 
the same number of * are significantly different when compared between each other (p < 0.05). 
 
 
5. Interaction with biomolecules 
The interaction of selected diiron complexes with a variety of biomolecules was studied to give insights 
into their mechanism of action. The reactivity of [7]CF3SO3 with a mononucleotide (guanosine 5'-
monophosphate, 5’-GMP) and an oligonucleotide DNA model (14-mer, 5'-ATACATGGTACATA-3'), 
which have been used as models for other metallodrugs,44 was evaluated. No significant interactions 
were observed between the mono- or oligonucleotide with [7]+. Small shifts in the 1H NMR spectrum 
(within 0.30 ppm) were detected after the incubation of [7]CF3SO3 with 5’-GMP compared to the 
spectra of the individual compounds. These shifts are influenced by the solution pH, most likely due to 
the different protonation states adopted by the phosphate group (pKa = 6.49 for PO4
2− of 5’-GMP).45 
The interaction of [2]CF3SO3, [3]CF3SO3, [7]CF3SO3, [10]CF3SO3, [11]CF3SO3, 21b and 21c with 
natural DNA was investigated using ethidium bromide displacement tests.46 Calf-thymus DNA was 
saturated with ethidium bromide (EB), producing the known fluorescence emission increase at the 
wavelengths typical of the EB/DNA intercalated species (λex = 520, λem = 595 nm). The addition of the 
selected diiron complexes resulted in a moderate drop in fluorescence indicating weak complex-DNA 
interactions through a non-intercalative binding mode (Figure 5). Interestingly, a significantly higher 
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DNA affinity was found for 21c, probably favoured by the more hydrophobic and less sterically 
hindered structure respect to the cationic diiron frame. This increase of affinity is not displayed by the 
homologous compound 21b, containing the alcohol function and lacking the phenyl group. 
 
Figure 5. Ethidium bromide displacement tests for [2]CF3SO3, [3]CF3SO3, [7]CF3SO3, [10]CF3SO3, [11]CF3SO3, 
21b and 21c: each complex was added to ethidium-saturated DNA; CDNA = 1.4·10
−4 M, CEB = 5.9·10
-5 M, NaCl 
0.1 M, NaCac 0.01 M, λex = 520 nm, λem= 595 nm, T = 25 °C. 
 
 
The affinity of the diiron complexes to proteins was investigated using established peptide and protein 
models, i.e. amyloid β-protein (residues 1-16), ubiquitin and bovine serum albumin (BSA).44,47 The 
interactions of [7]CF3SO3 with amyloid β-protein and ubiquitin were assessed using mass 
spectrometry. Following incubation, no adducts were found but [7]+ was observed as an unbound 
cation (m/z 394.019) alongside additional peaks related to the loss of one (m/z 366.023) and two (m/z 
338.029) carbonyls. The overall positively charged biomolecules were identified in association with 
one, two or three triflate anions. Mass spectrometry analyses of BSA incubated with [2]CF3SO3, 
[7]CF3SO3, [10]CF3SO3 and [11]CF3SO3 led to recognition of the respective complex cation peaks, but 
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no adduct identification. Additionally, the interaction of [2]CF3SO3, [7]CF3SO3, [10]CF3SO3 and 
[11]CF3SO3 with BSA was assessed using direct spectrofluorimetric titrations where aliquots of the 
complex were added to a BSA solution (λex = 280 nm, λem = 345 nm). For all tested complexes, a 
decrease in BSA fluorescence emissions was observed (Figure S49). A Stern-Volmer analysis of the 
fluorescence data at different temperatures (10-40 °C range, Table S3) agrees with the static quenching 
of the protein emission suggesting adduct formation.48 Equilibrium data for the distinct systems at 
variable temperatures were evaluated using the HypSpec® software and reported in the form of a van’t 
Hoff plot (Supporting Information, Figures S50-S51). Due to the narrow temperature range and the 
application of a simple model to the complex protein substrate, the trends must be considered as 
indicative. [2]CF3SO3, [7]CF3SO3, [10]CF3SO3 and [11]CF3SO3 lie in a common stripe and display 
positive ∆H and ∆S values. This data outlines entropically driven hydrophobic interactions,49 
suggesting that the protein binding does not significantly contribute to the anticancer activity.  
 
6. Final remarks on the cytotoxic activity 
The diiron complexes probably exert their cytotoxicity by means of more than one mechanism of 
action, involving ROS production and limited interactions with DNA, but not proteins. Clean 
fragmentation, initiated by mono-electron reduction, might be viable for those compounds containing R 
and/or R′ electron withdrawing groups, according to electrochemical data. This reaction is expected to 
proceed via Fe(0) elimination leading to mononuclear Fe(II) derivatives (Scheme 2), with different 
antiproliferative activities (compare data on 21b and 21c). It is possible that the high level of 
cytotoxicity and the significant selectivity detected for [11]CF3SO3 is correlated to its partial 
conversion into 21c, which exhibits a cytotoxic behaviour ascribable to both ROS generation (allowed 
by accessible oxidation potential) and DNA binding.  
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Conclusions 
Cationic diiron vinyliminium complexes, in the form of their triflate salts, possess an amphiphilic 
nature due to the combination of net positive charge with non-polar fragments. They exhibit acceptable 
water solubility and are reasonably stable in water and cell culture medium. Their structure and 
physico-chemical properties can be modulated by adjusting the isocyanide/alkyne combination that 
generates the vinyliminium moiety. The availability of commercial alkynes, the large scope and the 
regio-specificity of the alkyne insertion reaction, tolerating various functional groups (Scheme 1), 
offers wide structural variability. We synthesized a series of vinyliminium complexes, including novel 
complexes containing various functionalities within the vinyliminium frame, which was assessed for 
the antiproliferative activity. In general, the activity is variable, ranging from inactive to nanomolar 
concentrations, against A2780 and A2780cisR cell lines. A general trend indicates that the IC50 values 
decrease with increasing lipophilicity but, importantly, the complexes remain water soluble. Up to a 
seven fold selectivity has been observed towards the cancerous A2780 cell line compared to the non-
tumoural HEK-293 cell line for the most active complexes. Investigations suggest that multiple effects 
could be responsible for the cytotoxicity of the complexes, including ROS production and DNA 
binding, but not protein binding. The ROS generation and especially the DNA binding may be 
enhanced by fragmentation of the diiron compounds to monoiron species. 
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Experimental 
1. Synthetic procedures and characterization of products 
General details. Organic reactants (TCI Europe or Merck) and Fe2Cp2(CO)4 (Strem) were commercial 
products of the highest purity available. Compounds [1a-c]CF3SO3 
27 and [10]CF3SO3 
50 were prepared 
according to published procedures. Chromatography separations were carried out on columns of 
deactivated alumina (Merck, 4% w/w water). Infrared spectra of solid samples were recorded on a 
Perkin Elmer Spectrum One FT-IR spectrometer, equipped with a UATR sampling accessory (4000-
400 cm-1 range). Infrared spectra of solutions were recorded on a Perkin Elmer Spectrum 100 FT-IR 
spectrometer with a CaF2 liquid transmission cell (2300-1500 cm
-1 range). UV-Vis spectra were 
recorded on an Ultraspec 2100 Pro spectrophotometer. IR and UV-Vis spectra were processed with 
Spectragryph software.51 NMR spectra were recorded at 298 K on a Bruker Avance II DRX400 
instrument equipped with a BBFO broadband probe. Chemical shifts (expressed in parts per million) 
are referenced to the residual solvent peaks 52 (1H, 13C) or to external standard (19F, CFCl3). NMR 
spectra were assigned with the assistance of 1H-13C (gs-HSQC and gs-HMBC) correlation 
experiments.53 NMR signals due to a second isomeric form are italicized. RAMAN analysis was 
conducted with a Renishaw Invia micro-Raman instrument equipped with a Nd:YAG laser working at 
532 nm and 0.1 mW, integration time 10 s. Carbon, hydrogen and nitrogen analyses were performed on 
a Vario MICRO cube instrument (Elementar). 
Synthesis of diiron vinyliminium complexes. In a typical procedure, [1a-c]CF3SO3 (ca. 0.5 mmol) was 
dissolved into acetonitrile (10 mL) and treated with Me3NO (1.3 eq.). The resulting mixture was stirred 
for 1 hour, and progressive darkening of the solution was observed. The complete conversion of the 
starting material into the acetonitrile adduct [Fe2Cp2(CO)(µ-CO)(NCMe){µ-CNMe(R)}]CF3SO3 (R = 
Me, Xyl, CH2Ph) was confirmed by IR spectroscopy. The volatiles were removed under vacuum, thus 
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the dark brown residue was dissolved into dichloromethane (ca. 20 mL). The solution was treated with 
the appropriate alkyne (ca. 1.3 eq.), and the mixture was stirred at room temperature for 48 hours, 
under a nitrogen atmosphere. The final mixture was charged on an alumina column. Elution with 
CH2Cl2 and CH2Cl2/THF mixtures allowed the removal of unreacted alkyne and impurities, then a 
fraction corresponding to the desired product was collected using MeCN/MeOH 9:1 (v/v) as eluent. 
Removal of the solvent under reduced pressure afforded the product. Compounds [2,7-9,11-12,17-
18]CF3SO3 were prepared in comparable yields also in gram-scale quantities (1-4 g), without any 
modification of the general procedure. All compounds, [1-19]CF3SO3, resulted indefinitely air stable. 
 
[Fe2Cp2(CO)(µ-CO){µ-η
1
:η3-C3(Ph)C2HC1NMe2}]CF3SO3, [2]CF3SO3 (Chart 1) 
Chart 1. Structure of [2]+. 
 
From [1a]CF3SO3 and phenylacetylene. Brown solid, yield 74%. Anal. calcd. for C24H22F3Fe2NO5S: C, 
47.63; H, 3.66; N, 2.31. Found: C, 47.39; H, 3.80; N, 2.45. IR (CH2Cl2): ῦ/cm
-1 = 1993vs (CO), 1809s 
(µ-CO), 1677m (C2C1N). 1H NMR (acetone-d6): δ/ppm = 7.84, 7.57, 7.43 (m, 5 H, Ph); 5.44, 5.25 (s, 
10 H, Cp); 4.68 (s, 1 H, C2H); 4.05, 3.47 (s, 6 H, NMe). 13C{1H} NMR (acetone-d6): δ/ppm = 255.9 (µ-
CO); 225.0 (C1); 210.1 (CO); 203.8 (C3); 156.3 (ipso-Ph); 128.4, 127.5, 127.0 (Ph); 91.6, 87.8 (Cp); 
53.0 (C2); 51.1, 44.4 (NMe).  1H NMR (D2O): δ/ppm = 7.67, 7.51, 7.38 (m, 5 H, Ph); 5.16, 5.04 (s, 10 
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H, Cp); 4.49 (s, 1 H, C2H); 3.79, 3.23 (s, 6 H, NMe). 19F NMR (D2O): δ/ppm = −78.9. λmax/nm 
(ε/M−1·cm−1, CH2Cl2) = 223 (4.8·10
4), 270 (2.4·104). 
 
[Fe2Cp2(CO)(µ-CO){µ-η
1
:η
3
-C
3
(2-naphthyl)C
2
HC
1
NMe2}]CF3SO3, [3]CF3SO3 (Chart 2) 
Chart 2. Structure of [3]+. 
 
From [1a]CF3SO3 and 1-ethynylnaphthalene. Brown solid, yield 96%. Anal. calcd. for 
C28H24F3Fe2NO5S: C, 51.32; H, 3.69; N, 2.14. Found: C, 51.24; H, 3.73; N, 2.24. IR (CH2Cl2): ῦ/cm
-1 = 
1988vs (CO), 1809s (µ-CO), 1687m (C2C1N). 1H NMR (dmso-d6): δ/ppm = 8.08, 8.01, 7.88, 7.74, 7.60 
(m, 7 H, C10H7); 5.48, 5.06 (s, 10 H, Cp); 4.73 (s, 1 H, C
2H); 3.90, 3.33 (s, 6 H, NMe). 13C{1H} NMR 
(dmso-d6): δ/ppm = 257.0 (µ-CO); 224.1 (C
1); 211.5 (CO); 202.7 (C3); 153.0 (ipso-C10H7); 133.8, 
129.9, 129.0, 127.6, 127.1, 126.5, 126.3, 125.7 (C10H7); 92.3, 88.5 (Cp); 54.8 (C
2); 51.8, 44.7 (NMe). 
1H NMR (D2O): δ/ppm = 7.98, 7.70, 7.57 (m, 7 H, C10H7); 5.28, 4.90 (s, 10 H, Cp); 4.63 (s, 1 H, C
2H); 
3.84, 3.30 (s, 6 H, NMe). 19F NMR (D2O): δ/ppm = −78.9. λmax/nm (ε/M
−1·cm−1, CH2Cl2) = 228 
(4.9·104), 310 (1.5·104). 
 
[Fe2Cp2(CO)(µ-CO){µ-η
1
:η3-C3(3-C6H4OH)C
2
HC
1
NMe2}]CF3SO3, [4]CF3SO3 (Chart 3) 
Chart 3. Structure of [4]+. 
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From [1a]CF3SO3 and 3-hydroxyphenylacetylene. Brown solid, yield 71%. Anal. calcd. for 
C24H22F3Fe2NO6S: C, 46.40; H, 3.57; N, 2.25. Found: C, 46.30; H, 3.49; N, 2.36. IR (CH2Cl2): ῦ/cm
-1 = 
1990vs (CO), 1806s (µ-CO), 1675m (C2C1N), 1593 (arom). 1H NMR (acetone-d6): δ/ppm = 8.87 (br, 1 
H, OH); 7.36, 7.22, 6.88 (m, 4 H, C6H4); 5.39, 5.25 (s, 10 H, Cp); 4.63 (s, 1 H, C
2H); 4.02, 3.44 (s, 6 H, 
NMe). 13C{1H} NMR (acetone-d6): δ/ppm = 256.1 (µ-CO); 225.1 (C
1); 211.1 (CO); 204.1 (C3); 157.6, 
157.4 (ipso-C6H4 + COH); 129.4, 118.5, 114.3, 114.0 (C6H4); 91.7, 87.7 (Cp); 52.6 (C
2); 50.8, 44.2 
(NMe). 1H NMR (D2O): δ/ppm = 7.38, 7.22, 7.13, 6.88 (m, 4 H, C6H4OH); 5.15, 5.04 (s, 10 H, Cp); 
4.48 (s, 1 H, C2H); 3.78, 3.22 (s, 6 H, NMe). 19F NMR (D2O): δ/ppm = −78.9. λmax/nm (ε/M
−1·cm−1, 
CH2Cl2) = 224 (4.2·10
4), 269 (1.8·104), 300 (1.5·104). 
 
[Fe2Cp2(CO)(µ-CO){µ-η
1
:η
3
-C
3
(4-C6H4CO2H)C
2
HC
1
NMe2}]CF3SO3, [5]CF3SO3 (Chart 4) 
Chart 4. Structure of [5]+. 
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From [1a]CF3SO3 and 4-ethynylbenzoic acid. Brown-green solid, yield 87%. Anal. calcd. for 
C25H22F3Fe2NO7S: C, 46.25; H, 3.42; N, 2.16. Found: C, 46.07; H, 3.53; N, 2.25. IR (CH2Cl2): ῦ/cm
-1 = 
1993vs (CO), 1807s (µ-CO), 1697m (COOH), 1677m (C2C1N), 1604w (C=C), 1590w (C=C). 1H NMR 
(acetone-d6): δ/ppm = 8.19, 7.96 (br, 4 H, C6H4); 5.46, 5.27 (s, 10 H, Cp); 4.73 (s, 1 H, C
2H); 4.05, 
3.48 (s, 6 H, NMe). 13C{1H} NMR (acetone-d6): δ/ppm = 255.3 (µ-CO); 224.6 (C
1); 209.8 (CO); 201.0 
(C3); 166.5 (CO2H); 160.5, 150.0 (ipso-C6H4); 129.8, 127.7 (orto-C6H4 + meta-C6H4); 91.6, 87.8 (Cp); 
52.7 (C2); 51.0, 44.2 (NMe). 1H NMR (D2O): δ/ppm = 7.98, 7.70 (m, 4 H, C6H4); 5.18, 5.04 (s, 10 H, 
Cp); 4.54 (s, 1 H, C2H); 3.79, 3.23 (s, 6 H, NMe). 19F NMR (D2O): δ/ppm = −78.6. λmax/nm 
(ε/M−1·cm−1, CH2Cl2) = 223 (3.1·10
4), 268 (1.8·104). 
 
[Fe2Cp2(CO)(µ-CO){µ-η
1
:η
3
-C
3
(3-tiophenyl)C
2
HC
1
NMe2}]CF3SO3, [6]CF3SO3 (Chart 5) 
Chart 5. Structure of [6]+. 
 
From [1a]CF3SO3 and 3-ethynylthiophene. Brown solid, yield 71%. Anal. calcd. for 
C22H20F3Fe2NO5S2: C, 43.23; H, 3.30; N, 2.29. Found: C, 43.11; H, 3.37; N, 2.40. IR (CH2Cl2): ῦ/cm
-1 
= 1991vs (CO), 1808s (µ-CO), 1687m (C2C1N), 1606w-m (arom). 1H NMR (acetone-d6): δ/ppm = 
7.82, 7.72 (m, 3 H, C4H3S); 5.36, 5.33 (s, 10 H, Cp); 4.72 (s, 1 H, C
2H); 4.04, 3.45 (s, 6 H, NMe). 
13C{1H} NMR (acetone-d6): δ/ppm = 255.9 (µ-CO); 225.2 (C
1); 210.1 (CO); 195.4 (C3); 157.6 (ipso-
C4H3S); 129.3, 126.2, 120.1 (C4H3S); 91.4, 87.8 (Cp); 52.5 (C
2); 50.9, 44.2 (NMe). 1H NMR (D2O): 
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δ/ppm = 7.56, 7.51 (m, 3 H, C4H3S); 5.10, 5.09 (s, 10 H, Cp); 4.53 (s, 1 H, C
2H); 3.76, 3.21 (s, 6 H, 
NMe2). 
19F NMR (D2O): δ/ppm = −78.9. λmax/nm (ε/M
−1·cm−1, CH2Cl2) = 223 (5.2·10
4), 264 (2.6·104), 
302 (2.0·104). 
 
 [Fe2Cp2(CO)(µ-CO){µ-η
1
:η
3
-C
3
(Me)C
2
HC
1
NMe2}]CF3SO3, [7]CF3SO3 (Chart 6) 
Chart 6. Structure of [7]+. 
 
From [1a]CF3SO3 and propyne (in THF solution, ca. 1 mol/L). Brown solid, yield 96%. Anal. calcd. 
for C19H20F3Fe2NO5S: C, 42.02; H, 3.71; N, 2.58. Found: C, 41.89; H, 3.64; N, 2.68. IR (CH2Cl2): 
ῦ/cm-1 = 1990vs (CO), 1806s (µ-CO), 1684m (C2C1N). 1H NMR (dmso-d6): δ/ppm = 5.48, 5.14 (s, 10 
H, Cp); 4.51 (s, 1 H, C2H); 3.82, 3.77 (s, 6 H, NMe + C3Me); 3.18 (s, 6 H, NMe). 13C{1H} NMR 
(dmso-d6): δ/ppm = 258.4 (µ-CO); 225.6 (C
1); 211.4 (CO); 208.0 (C3); 91.2, 88.0 (Cp); 52.1 (C2); 51.0, 
44.8 (NMe2); 41.7 (C
3Me). 1H NMR (D2O): δ/ppm = 5.28, 4.94 (s, 10 H, Cp); 4.39 (s, 1 H, C
2H); 3.75, 
3.70 (s, 6 H, NMe + C3Me); 3.13 (s, 3 H, NMe). 19F NMR (D2O): δ/ppm = −78.9. λmax/nm 
(ε/M−1·cm−1, CH2Cl2) = 226 (2.4·10
4), 294 (8.6·103), 406 (2.5·103). 
 
 [Fe2Cp2(CO)(µ-CO){µ-η
1
:η
3
-C
3
(CO2Me)C
2
(CO2Me)C
1
NMe2}]CF3SO3, [8]CF3SO3 (Chart 7) 
Chart 7. Structure of [8]+. 
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From [1a]CF3SO3 and dimethyl acetylenedicarboxylate. Brown solid, yield 88%. Anal. calcd. for 
C22H23F3Fe2NO9S: C, 40.89; H, 3.59; N, 2.17. Found: C, 40.95; H, 3.38; N, 2.25. IR (CH2Cl2): ῦ/cm
-1 = 
2007vs (CO), 1830s (µ-CO), 1733s (CO2Me), 1715s (CO2Me), 1685m (C
2C1N). 1H NMR (dmso-
d6/D2O 3:1): δ/ppm = 5.37, 5.22 (s, 10 H, Cp); 4.01, 3.83 (s, 6 H, CO2Me); 3.74, 3.19 (s, 6 H, NMe2).
 
13C{1H} NMR (dmso-d6/D2O 3:1): δ/ppm = 251.6 (µ-CO); 218.2 (C
1); 208.7 (CO); 187.3 (C3); 176.8, 
166.8 (CO2Me); 92.1, 89.9 (Cp); 52.5 (C
2); 54.1, 53.3 (CO2Me); 51.8, 45.6 (NMe).
 1H NMR (D2O): 
δ/ppm = 5.30, 5.15 (s, 10 H, Cp); 4.09, 3.83 (s, 6 H, CO2Me); 3.78, 3.22 (s, 6 H, NMe2). 
19F NMR 
(D2O): δ/ppm = −78.9. λmax/nm (ε/M
−1·cm−1, CH2Cl2) = 226 (3.2·10
4), 291 (1.4·104), 389 (4.3·103). 
 
[Fe2Cp2(CO)(µ-CO){µ-η
1
:η
3
-C
3
(Me)C
2
(Me)C
1
NMe2}]CF3SO3, [9]CF3SO3 (Chart 8) 
Chart 8. Structure of [9]+. 
 
From [1a]CF3SO3 and 2-butyne. Dark green solid, yield 94%. Anal. calcd. for C20H22F3Fe2NO5S: C, 
43.12; H, 3.98; N, 2.51. Found: C, 42.90; H, 3.91; N, 2.60. IR (CH2Cl2): ῦ/cm
-1 = 1987vs (CO), 1806s 
(µ-CO), 1665m (C2C1N). 1H NMR (dmso-d6): δ/ppm = 5.44, 5.11 (s, 10 H, Cp); 3.74 (s, 3 H, C
3Me); 
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3.70, 3.09 (s, 6 H, NMe2); 1.83 (s, 3 H, C
2Me). 1H NMR (D2O): δ/ppm = 5.23, 4.89 (s, 10 H, Cp); 3.67, 
3.65 (s, 6 H, C3Me + NMe); 2.61 (s, 3 H, NMe); 1.76 (s, 3 H, C2Me). 19F NMR (D2O): δ/ppm = −78.8. 
λmax/nm (ε/M
−1·cm−1, CH2Cl2) = 225 (3.2·10
4), 265 (1.2·104), 295 (1.1·104). 
 
[Fe2Cp2(CO)(µ-CO){µ-η
1
:η
3
-C
3
(Ph)C
2
(Ph)C
1
NMe2}]CF3SO3, [10]CF3SO3 (Chart 9) 
Chart 9. Structure of [10]+. 
 
From [1a]CF3SO3 and diphenylacetylene. Dark green solid, yield 52%. Crystals suitable to X-ray 
analysis were obtained from a concentrated water/dmso solution at 20 °C. Anal. calcd. for 
C30H26F3Fe2NO5S: C, 52.89; H, 3.85; N, 2.06. Found: C, 52.80; H, 3.72; N, 2.13. IR (CH2Cl2): ῦ/cm
-1 = 
1995vs (CO), 1813s (µ-CO), 1662m (C2C1N). 1H NMR (acetone-d6): δ/ppm = 7.86, 7.58, 7.41, 7.28, 
7.20, 7.14 (m, 10 H, Ph); 5.67, 5.29 (s, 10 H, Cp); 4.11, 2.85 (s, 6 H, NMe). 1H NMR (D2O): δ/ppm = 
7.20, 7.12, 7.01 (m, 7 H, C10H7); 5.40, 5.06 (s, 10 H, Cp); 3.82, 2.88 (s, 6 H, NMe2). λmax/nm 
(ε/M−1·cm−1, CH2Cl2) = 241 (4·10
4), 323 (5·103). 
 
[Fe2Cp2(CO)(µ-CO){µ-η
1
:η3-C3(Ph)C2HC1N(Me)(Xyl)}]CF3SO3, [11]CF3SO3 (Chart 10) 
Chart 10. Structure of [11]+. 
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From [1b]CF3SO3 and phenylacetylene. Brown, yield 74%. Anal. calcd. for C31H28F3Fe2NO5S: C, 
53.55; H, 4.06; N, 2.01. Found: C, 53.68; H, 3.93; N, 2.07. IR (CH2Cl2): ῦ/cm
-1 = 2003vs (CO), 1819s 
(µ-CO), 1629m (C2C1N). 1H NMR (dmso-d6/D2O 3:1): δ/ppm = 7.46, 7.38, 7.23, 7.06 (8 H, Ph + 
C6H3Me2); 5.61, 5.33, 5.28, 4.97 (s, 10 H, Cp); 4.25, 3.58 (s, 3 H, NMe); 4.10 (s, 1 H, C
-H); 2.22, 1.78 
(s, 6 H, C6H3Me2), E/Z ratio = 9.
 1H NMR (D2O): δ/ppm = 5.38, 5.16, 5.11, 4.88 (s, 10 H, Cp); 4.18, 
3.53 (s, 3 H, NMe); 2.41, 2.12, 1.94, 1.82 (s, 6 H, C6H3Me2), Z/E ratio = ca. 1.5. λmax/nm (ε/M
−1·cm−1, 
CH2Cl2) = 227 (3.0·10
4), 269 (1.5·104), 304 (1.1·104). 
 
[Fe2Cp2(CO)(µ-CO){µ-η
1
:η
3
-C
3
(Me)C
2
HC
1
N(Me)(Xyl)}]CF3SO3, [12]CF3SO3 (Chart 11) 
Chart 11. Structure of [12]+. 
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From [1b]CF3SO3 and propyne (in THF solution, ca. 1 mol/L). Brown solid, yield 85%. Anal. calcd. 
for C26H26F3Fe2NO5S: C, 49.31; H, 4.14; N, 2.21. Found: C, 49.25; H, 4.28; N, 2.30. IR (CH2Cl2): 
ῦ/cm-1 = 2000vs (CO), 1815s (µ-CO), 1632m (C2C1N). 1H NMR (dmso-d6): δ/ppm = 7.23-7.18, 7.02-
7.00 (m, 3 H, C6H3Me2); 5.61, 5.33 (s, 10 H, Cp); 4.18 (s, 1 H, C
2H); 4.16 (s, 3 H, NMe); 3.77 (s, 3 H, 
C3Me); 2.26, 1.72 (s, 6 H, C6H3Me2).
 1H NMR (D2O): δ/ppm = 7.37, 7.13, 6.95 (m, 3 H, C6H3Me2); 
5.40, 5.13 (s, 10 H, Cp); 4.10 (s, 3 H, NMe); 4.07 (s, 1 H, C2H); 3.67 (s, 3 H, C3Me); 2.17, 1.70 (s, 6 H, 
C6H3Me2). 
19F NMR (D2O): δ/ppm = −78.6. λmax/nm (ε/M
−1·cm−1, CH2Cl2) = 223 (6.1·10
4), 261 
(2.4·104), 314 (1.7·104). 
  
[Fe2Cp2(CO)(µ-CO){µ-η
1
:η3-C3(CH2OH)C
2
HC
1
N(Me)(Xyl)}]CF3SO3, [13]CF3SO3 (Chart 12) 
Chart 12. Structure of [13]+. 
 
From [1b]CF3SO3 and propargyl alcohol. Dark brown solid, yield 80%. Anal. calcd. for 
C26H26F3Fe2NO6S: C, 48.10; H, 4.04; N, 2.16. Found: C, 47.90; H, 3.95; N, 2.22. IR (CH2Cl2): ῦ/cm
-1 = 
2001vs (CO), 1810s (µ-CO), 1631m (C2C1N). 1H NMR (dmso-d6/D2O 3:2): δ/ppm = 7.37, 7.14, 6.94 
(m, 3 H, C6H3Me2); 5.85, 5.62, 5.37, 4.68 (m, 2 H, 
2JHH = 16 Hz, CH2); 5.44, 5.16 (s, 10 H, Cp); 4.60 
(s, 1 H, C2H); 4.07, 3.39 (s, 3 H, NMe); 2.35, 2.15, 1.86, 1.67 (s, 6 H, C6H3Me2), E/Z ratio = 9. 
1H 
NMR (D2O): δ/ppm = 7.41, 7.24, 7.17, 6.97 (m, 3 H, C6H3Me2); 5.95-5.74 (m, 2 H, 
2JHH = 16 Hz, 
CH2); 5.43, 5.36, 5.16 (s, 10 H, Cp); 4.12, 3.45 (s, 3 H, NMe); 2.40, 2.17, 1.90, 1.71 (s, 6 H, C6H3Me2). 
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E/Z ratio = 7. 19F NMR (D2O): δ/ppm = −78.8. λmax/nm (ε/M
−1·cm−1, CH2Cl2) = 226 (4.1·10
4), 260 
(1.8·104), 309 (1.4·104), 416 (4.5·103). 
 
[Fe2Cp2(CO)(µ-CO){µ-η
1
:η
3
-C
3
(3-tiophenyl)C
2
HC
1
N(Me)(Xyl)}]CF3SO3, [14]CF3SO3 (Chart 13) 
Chart 13. Structure of [14]+. 
 
From [1b]CF3SO3 and 3-ethynylthiophene. Brown solid, yield 75%. Crystals suitable to X-ray analysis 
were obtained from a CH2Cl2 solution layered with Et2O and stored at −30 °C. Anal. calcd. for 
C29H26F3Fe2NO5S2: C, 49.66; H, 3.74; N, 2.00. Found: C, 49.47; H, 3.67; N, 2.08. IR (CH2Cl2): ῦ/cm
-1 
= 2005vs (CO), 1818s (µ-CO), 1631m (C2C1N). IR (solid state): ῦ/cm-1 = 3112w, 2938w, 1995vs (CO), 
1802s (CO), 1625m-s (C2C1N), 1584w, 1521vw, 1469w, 1435w, 1417w, 1263vs, 1223m-s, 1189w, 
1146s, 1119m-sh, 1083w, 1064m, 1030vs, 1030vs, 1010m-sh, 961w, 859m, 843m-s, 780s, 752m, 
737m-s, 705w, 682m, 654m. 1H NMR (acetone-d6): δ/ppm = 7.65-7.48, 7.26-7.08 (m, 6 H, C4H3S + 
C6H3Me2); 5.62, 5.46, 5.41, 5.02 (s, 10 H, Cp); 4.41, 3.72 (s, 3 H, NMe); 4.33 (s, 1 H, C
2H); 2.35, 1.88 
(s, 6 H, C6H3Me2), E/Z ratio = 9. 
13C{1H} NMR (acetone-d6): δ/ppm = 253.6 (µ-CO); 232.5 (C
1); 210.4 
(CO); 200.2 (C3); 157.1 (ipso-C4H3S); 145.4 (ipso-C6H3Me2); 132.1, 131.3, 129.6, 129.3, 129.0 
(C6H3Me2); 126.3, 119.7 (C4H3S); 92.3, 88.2 (Cp); 53.2 (C
2); 45.6 (NMe); 17.3, 16.6 (C6H3Me2).
 1H 
NMR (D2O): δ/ppm = 9.37-7.13 (m, 6 H, C4H3S + C6H3Me2); 5.36, 5.15 (s, 10 H, Cp); 4.15 (s, 3 H, 
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NMe); 2.31, 1.97 (s, 6 H, C6H3Me2). 
19F NMR (D2O): δ/ppm = −79.1. λmax/nm (ε/M
−1·cm−1, CH2Cl2) = 
227 (4.3·104), 270 (2.2·104), 300 (1.6·104). 
 
[Fe2Cp2(CO)(µ-CO){µ-η
1
:η
3
-C
3
(2-naphthyl)C
2
HC
1
N(Me)(Xyl)}]CF3SO3, [15]CF3SO3 (Chart 14) 
Chart 14. Structure of [15]+. 
 
From [1b]CF3SO3 and 1-ethynylnaphthalene. Brown solid, yield 93%. Anal. calcd. for 
C35H30F3Fe2NO5S: C, 56.40; H, 4.06; N, 1.88. Found: C, 56.30; H, 3.96; N, 1.96. IR (CH2Cl2): ῦ/cm
-1 = 
1998vs (CO), 1818s (µ-CO), 1627s (C2C1N). 1H NMR (dmso-d6): δ/ppm = 8.11-7.07 (m, 10 H, C10H7 
+ C6H3Me2); 5.71, 5.21, 5.17, 5.07 (s, 10 H, Cp); 4.29, 3.62 (s, 3 H, NMe); 4.24 (s, 1 H, C
2H); 2.46, 
2.16, 2.05, 1.87 (s, 6 H, C6H3Me2), E/Z ratio = 4. 
13C{1H} NMR (dmso-d6): δ/ppm = 255.1 (µ-CO); 
232.1 (C1); 211.9 (CO); 206.0 (C3); 153.0 (ipso-C10H7); 145.7 (ipso-C6H3Me2); 133.7, 132.1, 131.2, 
129.8, 129.5, 129.0, 127.8, 126.6, 126.3, 126.0, 125.1, 124.8 (C10H7 + C6H3Me2); 93.2, 93.1, 89.1, 88.5 
(Cp); 55.5 (C2); 51.3, 45.8 (NMe); 18.9, 18.0, 17.8, 17.3 (C6H3Me2).
 1H NMR (D2O): δ/ppm = 8.36-
7.62 (m, 10 H, C10H7 + C6H3Me2); 5.36, 5.04, 5.07, 4.98 (s, 10 H, Cp); 3.62 (s, 3 H, NMe); 2.88, 2.41, 
2.22, 2.02 (s, 6 H, C6H3Me2), Z/E ratio = ca. 2. 
19F NMR (D2O): δ/ppm = −79.1. λmax/nm (ε/M
−1·cm−1, 
CH2Cl2) = 228 (4.2·10
4), 313 (1.3·104). 
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[Fe2Cp2(CO)(µ-CO){µ-η
1
:η
3
-C
3
(2-pyridyl)C
2
HC
1
N(Me)(Xyl)}]CF3SO3, [16]CF3SO3 (Chart 15) 
Chart 15. Structure of [16]+. 
 
From [1b]CF3SO3 and 2-ethynylpyridine. Dark brown solid, yield 59%. Anal. calcd. for 
C30H27F3Fe2N2O5S: C, 51.75; H, 3.91; N, 4.02. Found: C, 51.93; H, 3.76; N, 4.09. IR (CH2Cl2): ῦ/cm
-1 
= 2003vs (CO), 1819s (µ-CO), 1631m (C2C1N). 1H NMR (acetone-d6): δ/ppm = 8.78, 7.89, 7.50-7.38, 
7.27, 7.20, 7.10 (m, 7 H, C5H4N + C6H3Me2); 5.64, 5.41, 5.37, 5.07 (s, 10 H, Cp); 4.47 (s, 1 H, C
2H); 
4.42, 3.76 (s, 3 H, NMe); 2.60, 2.35, 2.09, 1.89 (s, 6 H, C6H3Me2), E/Z ratio = ca. 8. 
13C{1H} NMR 
(dmso-d6): δ/ppm = 253.3 (µ-CO); 232.7 (C
1); 210.3 (CO); 171.4 (C3); 149.0, 145.3, 136.7, 132.1, 
131.3, 129.6, 129.3, 122.0, 121.7 (C5H4N + C6H3Me2); 91.9, 91.8, 88.7, 88.2 (Cp); 53.1 (C
2); 45.8 
(NMe); 17.3, 16.6 (C6H3Me2).
 1H NMR (D2O): δ/ppm = 8.62, 8.42, 8.01, 7.91, 7.77, 7.41, 7.34-6.99 
(m, 7 H, C5H4N + C6H3Me2); 5.38, 5.17, 5.12, 4.89 (s, 10 H, Cp); 4.33 (s, 1 H, C
2H); 4.18, 3.54 (s, 3 H, 
NMe); 2.41, 2.12, 1.94, 1.75 (s, 6 H, C6H3Me2), E/Z ratio = ca. 1.5. 
19F NMR (D2O): δ/ppm = −78.9. 
λmax/nm (ε/M
−1·cm−1, CH2Cl2) = 228 (4.2·10
4), 271 (2.2·104), 323 (1.3·104). 
 
[Fe2Cp2(CO)(µ-CO){µ-η
1
:η
3
-C
3
(CO2Me)C
2
(CO2Me)C
1
N(Me)(Xyl)}]CF3SO3, [17]CF3SO3 (Chart 
16) 
Chart 16. Structure of [17]+. 
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From [1b]CF3SO3 and dimethyl acetylenedicarboxylate. Dark orange solid, yield 82%. Anal. calcd. for 
C29H28F3Fe2NO9S: C, 47.37; H, 3.84; N, 1.90. Found: C, 47.12; H, 3.75; N, 1.98. IR (CH2Cl2): ῦ/cm
-1 = 
2007vs (CO), 1843s (µ-CO), 1733m (CO2Me), 1717m (CO2Me), 1629m (C
2C1N). 1H NMR (dmso-
d6/D2O 1:1): δ/ppm = 7.40, 7.21 (m, 3 H, C6H3Me2); 5.32, 4.86 (s, 10 H, Cp); 4.06, 3.83 (s, 6 H, 
CO2Me); 3.44 (s, 3 H, NMe); 2.44, 1.87 (s, 6 H, C6H3Me2). 
1H NMR (D2O): δ/ppm = 7.42, 7.2-7.0 (m, 
3 H, C6H3Me2); 5.34, 4.91 (s, 10 H, Cp); 4.13, 3.89 (s, 6 H, CO2Me); 3.51 (s, 3 H, NMe); 2.47, 1.90 (s, 
6 H, C6H3Me2). 
19F NMR (D2O): δ/ppm = −78.9. λmax/nm (ε/M
−1·cm−1, CH2Cl2) = 225 (4.1·10
4), 295 
(1.4·104), 404 (4.1·103). 
 
[Fe2Cp2(CO)(µ-CO){µ-η
1
:η
3
-C
3
(Me)C
2
(Me)C
1
N(Me)(Xyl)}]CF3SO3, [18]CF3SO3 (Chart 17) 
Chart 17. Structure of [18]+. 
 
Trans-[18]CF3SO3. From [1b]CF3SO3 and 2-butyne (ca. 3 equivalents). Dark green solid, yield 76%. 
Anal. calcd. for C27H28F3Fe2NO5S: C, 50.10; H, 4.36; N, 2.16. Found: C, 49.87; H, 4.47; N, 2.24. IR 
 
 
35 
 
 
(CH2Cl2): ῦ/cm
-1 = 1985vs (CO), 1823s (µ-CO), 1610m (C2C1N). 1H NMR (dmso-d6): δ/ppm = 7.43, 
7.35, 7.12, 6.90 (m, 3 H, C6H3Me2); 5.56, 4.88 (s, 10 H, Cp); 3.99 (s, 3 H, C
3Me); 3.56 (s, 3 H, NMe); 
2.61, 2.06 (s, 6 H, C6H3Me2); 2.22 (s, 3 H, C
2Me). λmax/nm (ε/M
−1·cm−1, CH2Cl2) = 224 (3.7·10
4), 264 
(1.6·104), 292 (1.3·104). 
Cis-[18]CF3SO3. This compound was obtained by heating a solution of trans-[18]CF3SO3 (ca. 0.40 
mmol) in methanol (15 mL), under nitrogen, for 3 hours. The final brown-red solution was dried under 
reduced pressure, the residue was dissolved into a small volume of CH2Cl2 and charged on alumina. 
Impurities were separated by using CH2Cl2/THF mixtures and neat THF as eluent. The product was 
obtained by using MeOH as eluent as a red fraction, which was dried under vacuum. Dark red solid, 
yield 91%. Anal. calcd. for C27H28F3Fe2NO5S: C, 50.10; H, 4.36; N, 2.16. Found: C, 49.78; H, 4.35; N, 
2.20. IR (CH2Cl2): ῦ/cm
-1 = 1987vs (CO), 1819s (µ-CO), 1610m (C2C1N). 1H NMR (acetone-d6): 
δ/ppm = 7.48, 7.35 (m, 3 H, C6H3Me2); 5.57, 4.88 (s, 10 H, Cp); 4.01 (s, 3 H, C
3Me); 3.57 (s, 3 H, 
NMe); 2.61, 2.06 (s, 6 H, C6H3Me2); 2.25 (s, 3 H, C
2Me). 1H NMR (D2O): δ/ppm = 7.38, 7.20, 7.12, 
6.89, 6.82 (m, 3 H, C6H3Me2); 5.29, 4.66 (s, 10 H, Cp); 3.77 (s, 3 H, C
3Me); 3.36 (s, 3 H, NMe); 2.41, 
1.90 (s, 6 H, C6H3Me2); 2.02 (s, 3 H, C
2Me).  λmax/nm (ε/M
−1·cm−1, CH2Cl2) = 226 (4.0·10
4), 265 
(2.0·104), 302 (1.7·104). 
 
[Fe2Cp2(CO)(µ-CO){µ-η
1
:η
3
-C
3
(Ph)C
2
HC
1
N(Me)(CH2Ph)}]CF3SO3, [19]CF3SO3 (Chart 18). 
Chart 18. Structure of [19]+. 
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From [1c]CF3SO3 and phenylacetylene. Brown solid, yield 72%. Anal. calcd. for C30H26F3Fe2NO5S: C, 
52.89; H, 3.85; N, 2.06. Found: C, 52.74; H, 3.96; N, 2.02. IR (CH2Cl2): ῦ/cm
-1 = 1991vs (CO), 1809s 
(µ-CO), 1666m (C2C1N). 1H NMR (acetone-d6): δ/ppm = 7.89-7.36 (Ph); 5.50, 5.48, 5.32, 5.30 (s, Cp); 
5.72, 5.41, 5.00, 4.82 (d, 2JHH = 14 Hz, CH2Ph); 4.77 (s, C
2H); 3.94, 3.20 (s, NMe). E/Z ratio = 1.6. 
13C{1H} NMR (acetone-d6): δ/ppm = 257.6, 256.1 (µ-CO); 226.4, 226.1 (C
1); 210.4, 210.3 (CO); 
204.9, 204.4 (C3); 156.5 (ipso-PhCH2); 133.4, 132.8 (ipso-Ph); 128.8, 129.7, 129.5, 129.4, 129.1, 
128.9, 128.5, 127.7, 127.0 (Ph); 92.0, 88.4, 88.3 (Cp); 68.1, 61.5 (CH2Ph); 53.4, 53.3 (C
2); 47.9, 42.4 
(NMe). 19F NMR (D2O): δ/ppm = −78.9. 
 
Synthesis and characterization of [FeCp(CO){C1N(Me)(Xyl)C2HC3(Ph)C(=O)}], 21c (Chart 19) 
Chart 19. Structure of 21c. 
 
 
 
37 
 
 
Compound [11]CF3SO3 (280 mg, 0.403 mmol) was dissolved in tetrahydrofuran (15 mL), then CoCp2 
(99 mg, 0.52 mmol) was added. The mixture was stirred at room temperature overnight, then it was 
passed through a short alumina pad using neat acetonitrile as eluent. The filtrated solution was dried 
under vacuum. The residue was dissolved in diethyl ether/dichloromethane mixture (1:1 v/v) and 
charged on alumina column. Elution with petroleum ether/diethyl ether mixtures allowed the removal 
of impurities, then the fraction corresponding to 21c was collected with neat diethyl ether. Removal of 
the solvent under vacuum afforded the title product as a brown, air stable solid. Yield 84% (respect to 
C1C2C3 chain). Anal. calcd. for C25H23FeNO2: C, 70.60; H, 5.45; N, 3.29. Found: C, 70.44; H, 5.57; N, 
3.14. IR (CH2Cl2): ῦ/cm
-1 = 1919vs (CO), 1612m (COacyl), 1571m (C
1N). IR (solid state): ῦ/cm−1 = 
3082w, 3029w, 2925w, 1907vs, 1614m (COacyl), 1571w-m (C
1N), 1471m, 1383m, 1352w, 1299w, 
1084s-br, 1015s-br, 879w, 798vs, 774vs, 719w, 696m, 656w. 1H NMR (acetone-d6): δ/ppm = 7.38-7.22 
(m, 8 H, C6H3Me2 + Ph); 6.96 (s, 1 H, C
2H); 4.73 (s, 5 H, Cp); 3.96 (s, 3 H, NMe); 2.32, 2.17 (s, 6 H, 
C6H3Me2). 
13C{1H} NMR (acetone-d6): δ/ppm = 264.7, 264.6 (COacyl + C
1); 221.9 (CO); 168.7 (C3); 
147.5 (C2); 145.5 (ipso-C6H3); 132.9, 132.7, 132.4, 129.1, 129.0, 128.9, 128.8, 128.7, 127.9 (C6H3Me2 
+ Ph); 85.1 (Cp); 48.8 (NMe); 17.0, 16.6 (C6H3Me2). Crystallization from a diethyl ether solution 
layered with pentane and stored at −30 °C afforded dark brown crystals of 21c. 
 
2. Solubility and stability in aqueous media 
a) Solubility in D2O. Each compound ([2-19]CF3SO3, ca. 0.05 mmol) was added to a D2O solution (0.7 
mL) of Me2SO2 (c = 7.1·10
-3 mol·L-1), and the resulting mixture was stirred at 21 °C for 8 hours. The 
saturated solution was filtrated and transferred into an NMR tube, then analyzed by 1H NMR 
spectroscopy. The concentration (i.e. solubility) was calculated by the relative integral with respect to 
Me2SO2 as internal standard [δ/ppm = 3.14 (s, 6H) in D2O)]. Solubility data in D2O for [2-19]CF3SO3 
are compiled in Table 1.  
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b) Stability in D2O or D2O/DMSO-d6 solutions. A mixture of the selected Fe compound ([2-
19]CF3SO3, ca. 4 mg) and D2O (0.9 mL) was stirred at room temperature for 30 minutes, and then 
filtered over celite and transferred into an NMR tube. D2O/DMSO-d6 mixtures were used for 
compounds with low water solubility (7:1 v/v for [13]+; 3:1 v/v for [12]+, [14]+; 1:1 v/v for [10]+, [15]+). 
The resulting solutions were analyzed by 1H NMR and then heated at 37 °C for 72 hours. After cooling 
to room temperature, the final solutions were separated from a minor amount of brown precipitate by 
filtration over celite, and analyzed by 1H NMR: in general, the resonances due to the starting material 
were clearly detected, together with minor additional signals which could not be assigned (3.8-1.0 
ppm). No other Fe-cyclopentadienyl species was found in solution. The precipitate (ca. 1.3 mg) 
obtained from [7]CF3SO3 (20 mg) was analyzed by Raman spectroscopy and identified as hematite 
(Raman shifts: 216, 284, 394 cm-1). NMR data for the tested compounds are given in the SI. For 
D2O/DMSO-d6 mixtures, 
1H chemical shift values are referenced to the DMSO-d6 residual peak as in 
pure D2O (δ/ppm = 2.71). The stability experiments were repeated with the addition of NaCl up to ca. 
0.1 M concentration, giving substantially analogous results. 
c) Stability in cell culture medium. Each compound ([2-19]CF3SO3, ca. 0.01 mmol) was dissolved in 
dmso (ca. 0.2 mL) in a glass tube, then 3 mL of RPMI-1640 medium (Merck; modified with sodium 
bicarbonate, without L-glutamine and phenol red, liquid, sterile-filtered, suitable for cell culture) were 
added. Compound 21c was dissolved in 1 mL dmso. The resulting mixture was maintained at 37 °C for 
72 h, then allowed to cool to room temperature and extracted with CH2Cl2 (7 mL). The organic phase 
was analyzed by IR spectroscopy (CH2Cl2 solution), cleanly showing the bands of the starting 
compound only, with the exception of the sample derived from [17]CF3SO3 (appearance of additional, 
intense band at 1629 cm−1). For those compounds that could not be efficiently recovered with CH2Cl2 
extraction, an aliquot of the aqueous phase was analyzed by mass spectrometry in positive ion scan 
mode with an API 4000 instrument (SCIEX), equipped with an electrospray source. The mass spectra 
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evidenced the presence of the diiron vinyliminium cation as the largely prevalent species ([5]+: 500.1; 
[12]+: 484.2; [13]+: 500.3 m/z), with the exception of the sample derived from [8]CF3SO3 (prevalent 
peak at 438.2 m/z). 
 
3. Determination of partition coefficients (Log Pow) 
Partition coefficients (Pow; IUPAC: KD partition constant
54), defined as Pow = corg/caq, where corg and caq 
are the molar concentrations of the selected compound in the organic and aqueous phases, respectively, 
and were determined by the shake-flask method and UV-Vis measurements.34 Values of Log Pow for 
[2-19]CF3SO3 are compiled in Table 1. All the operations were carried out at 21±1°C. De-ionized 
water and 1-octanol were mixed and vigorously stirred for 24 hours at room temperature to allow 
saturation of both phases, then separated by centrifugation and used for the following experiments. A 
solution of the selected Fe compound ([2-19]CF3SO3) in the aqueous phase (V = 10 mL) was prepared 
and its UV-Vis spectrum was recorded. An aliquot of the solution (Vaq = 3.0 mL) was then transferred 
into a test tube and the organic phase (Vorg = Vaq = 3.0 mL) was added. The mixture was vigorously 
stirred for 2 h and the resulting emulsion was centrifuged (2000 rpm, 15’). Hence the UV-Vis spectrum 
of the aqueous phase was recorded. The partition coefficient was then calculated as  =  
,	
  	

	

, 
where A0,aq and Aaq are the absorbance in the aqueous phase respectively before and after mixing with 
the organic phase.34 UV-Vis measurements were carried out using 1 cm quartz cuvettes. The 
wavelength of the maximum absorption of each compound was used for UV-Vis quantification. 
 
4. Electrochemistry 
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Cyclic voltammetry measurements were performed with a PalmSens4 instrument interfaced to a 
computer employing PSTrace5 electrochemical software. All potentials are reported vs. FeCp2. Current 
sign convention adopted: negative, currents/cathodic process; positive, currents/anodic process.  
Experiments in aqueous media. Phosphate buffer (PB) solution (Na2HPO4/KH2PO4, Σc(PO4) = 50 mM, 
pH = 7.3) was prepared with ultrapure H2O and used as supporting electrolytes. [FeCp2]PF6 (Sigma 
Aldrich) was used without further purification. The three-electrode home-built cell was equipped with a 
Pt sheet counter electrode, teflon-encapsulated glassy-carbon (GC) working electrode (BASi, ø 3 mm) 
and a quasi-reference Pt electrode. Prior to measurements, the working GC electrode was polished by 
the following procedure:55 manual rubbing with 0.3 µM Al2O3 slurry in water (eDAQ) for 2 min, then 
sonication in ultrapure water for 10 min, manual rubbing with 0.05 µM Al2O3 slurry in water (eDAQ) 
for 2 min, then sonication in ultrapure water for 10 min.  
The supporting electrolyte (5.0 mL) was introduced into the cell and deaerated by bubbling argon for 2-
3 minutes. The CV of the solvent was recorded. The analyte was then introduced (c ≈ 7·10−4 M) and 
voltammograms were recorded (0.1 V/s); a small amount of [FeCp2]PF6 was added to the solution, and 
a further voltammogram was repeated. Under the present experimental conditions, the one-electron 
reduction of ferrocenium occurred at E° = +0.41 V vs NHE. 
Experiments in organic solvents. HPLC grade THF (Sigma Aldrich) was distilled from CaH2 and 
stored under Ar over 3Å molecular sieves. [NnBu4]PF6 (Fluka, electrochemical grade) and Cp2Fe 
(Fluka) were used without further purification. CV measurements were carried out under Ar using 0.2 
M [NnBu4]PF6 in THF as the supporting electrolyte. The working and the counter electrodes consisted 
of a Pt disk and a Pt gauze, respectively, both sealed in a glass tube. A quasi-reference Pt electrode was 
employed as a reference. The three-electrode home-built cell was pre-dried by heating under vacuum 
and filled with argon. The Schlenk-type construction of the cell maintained anhydrous and anaerobic 
conditions. The solution of supporting electrolyte, prepared under argon, was introduced into the cell 
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and the CV of the solvent was recorded. The analyte was then introduced (c ≈ 7·10−4 M) and 
voltammograms were recorded (0.1 V/s); a small amount of ferrocene was added to the solution, and a 
further voltammogram repeated. Under the present experimental conditions, the one-electron reduction 
of ferrocene occurred at E° = +0.59 V vs SCE.  
Infrared (IR) spectro-electrochemical measurements were carried out using an optically transparent 
thin-layer electrochemical (OTTLE) cell equipped with CaF2 windows, platinum mini-grid working 
and auxiliary electrodes and silver wire pseudo-reference electrode.56 During the microelectrolysis 
procedures, the electrode potential was controlled by a PalmSens4 instrument interfaced to a computer 
employing PSTrace5 electrochemical software. Argon-saturated THF solutions of the analyzed 
compound, containing [NnBu4]PF6 0.2 M as the supporting electrolyte, were used. The in situ 
spectroelectrochemical experiments were performed by collecting IR spectra at fixed time intervals 
during the oxidation or reduction, obtained by continuously increasing or lowering the initial working 
potential at a scan rate of 2.0 mV/sec. IR spectra were recorded on a Perkin-Elmer FT-IR 1725X 
spectrophotometer and UV-Vis spectra on a Perkin-Elmer Lambda EZ201 spectrophotometer. 
 
5. X-ray crystallography 
Crystal data and collection details for [10]CF3SO3, [14]CF3SO3·0.5CH2Cl2, [15]CF3SO3·CH2Cl2, 
[16]CF3SO3·0.5CH2Cl2 and 21c are reported in Table S4. Data were recorded on a Bruker APEX II 
diffractometer equipped with a PHOTON100 detector using Mo–Kα radiation. Data were corrected for 
Lorentz polarization and absorption effects (empirical absorption correction SADABS).57 The 
structures were solved by direct methods and refined by full-matrix least-squares based on all data 
using F2.58 Hydrogen atoms were fixed at calculated positions and refined by a riding model. All non-
hydrogen atoms were refined with anisotropic displacement parameters. 
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6. Cell culture and cytotoxicity studies 
Human ovarian carcinoma (A2780 and A2780cisR) cell lines were obtained from the European 
Collection of Cell Cultures (ECACC, UK). The non-tumoral human embryonic kidney (HEK-293) cell 
line was obtained from ATCC (Sigma, Switzerland). RPMI-1640 GlutaMAX and DMEM GlutaMAX 
media were obtained from Life Technologies (Switzerland), fetal bovine serum (FBS) was obtained 
from Sigma, penicillin streptomycin solution was obtained from Life Technologies and cisplatin was 
obtained from TCI. 
The cells were routinely cultured in RPMI-1640 GlutaMAX (A2780 and A2780cisR) and DMEM 
GlutaMAX (HEK-293) medium containing 10% heat-inactivated FBS and 1% penicillin/streptomycin 
solution at 37 °C and CO2 (5%). The A2780cisR cell line was routinely treated with cisplatin (2 µM) in 
the medium. The cytotoxicity of the compounds was determined using the MTT assay (MTT = 3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide).59 Cells were seeded in flat-bottom 96-
well plates as a suspension in medium containing 10% heat-inactivated FBS and 1% 
penicillin/streptomycin solution (100 µL and approximately 4300 cells per well) and incubated for 24 
h. Stock solutions of compounds were prepared in DMSO and were rapidly diluted in medium. The 
solutions were sequentially diluted (final DMSO concentration of 0.5%) to give a compound 
concentration range (0 µM to 500 µM). Cisplatin was included as a positive control (0 µM to 100 µM). 
The compounds were added to the pre-incubated 96-well plates in 100 µL aliquots and the plates were 
incubated for 72 hours. For selected compounds undergoing ROS determination, the IC50 value was 
also assessed after 24 hours of incubation. MTT (20µL, 5 mg/mL in Dulbecco’s Phosphate Buffered 
Saline, DPBS) was added to the cells and the plates were incubated for further 4 h. The culture medium 
was aspirated, and the purple formazan crystals formed by the mitochondrial dehydrogenase activity of 
vital cells were dissolved in DMSO (100 µL per well). The absorbance of the resulting solutions, 
directly proportional to the number of surviving cells, was quantified at 590 nm using a SpectroMax 
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M5e multi-mode microplate reader (using SoftMax Pro software, version 6.2.2). The percentage of 
surviving cells was calculated from the absorbance of wells corresponding to the untreated control 
cells. The reported IC50 values (Table 4) are based on means from two independent experiments, each 
comprising four testings per concentration level. 
 
7. ROS determination 
The intracellular increase of reactive oxygen species (ROS) upon treatment of the analyzed complexes 
was measured by using the DCFH-DA (2′,7′-dichlorodihydroﬂuorescein diacetate, Sigma Aldrich) 
assay, based on cellular uptake of the non-ﬂuorescent diacetate following deacetylation by esterases 
(2′,7′-dichlorodihydroﬂuorescein, DCFH) and oxidation to the ﬂuorescent dichloroﬂuorescein (2′,7′-
dichloro-ﬂuorescein, DCF).60 Thus, A2780 and A2780cisR cells were seeded at concentration of 4·104 
cells/well/90 µL of complete growth medium into 96-well plates. After overnight incubation, the cells 
were treated following manufacturer protocol. The culture medium was supplemented with 100 µL of a 
solution containing the fluorogenic probe and cells were incubated with 5% CO2 at 37 °C. After 1 h, 
cells were exposed with a final concentration of 100 µM of the tested compound and 5% CO2 at 37 °C; 
the same concentration of H2O2 was used as a positive control. Stock solutions of compounds were 
prepared as described above; cells incubated with equal amounts of DMSO in supplemented RPMI 
were used as control. The fluorescence was measured up to 24 hours with an excitation wavelength of 
485 nm and with a 535 nm emission filter by Multilabel Counter (PerkinElmer, Waltham, USA). The 
analyses were conducted on triplicate and experimental data were reported as mean ± SD. Statistical 
differences were analyzed using one-way analysis of variance (ANOVA), and a Tukey test was used 
for post hoc analysis. A p-value <0.05 was considered statistically significant. 
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8. Interaction with biomolecules 
Guanosine 5'-monophosphate disodium salt hydrate (Merck), amyloid β-protein (residues 1-16, H-Asp-
Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-OH) as its trifluoroacetate salt 
(Bachem), ubiquitin from bovine erythrocytes (Merck), bovine serum albumin (BSA, crystallized and 
lyophilized powder) and 14-mer oligonucleotide 5'-ATACATGGTACATA-3' (Microsynth) were 
received from commercial suppliers. The latter species was desalted with five rounds of centrifugation 
using 3 kDa-cutoff Amicon Ultra centrifugal filters, according to manufacturer's instructions. Solutions 
of each of these biomolecules (100 to 500 µM) were incubated with [7]CF3SO3 in 1:1 to 1:10 ratio at 
37 °C for 24 h. Analogous solutions of BSA were incubated with [2,7,10,11]CF3SO3 in 1:1 ratio at 37 
°C for 24 h. All incubations were performed in sterile MilliQ water (samples for mass spectrometry 
analysis) or D2O (samples for NMR analysis). Mass spectrometry measurements were performed either 
with LTQ Orbitrap Elite (Thermo Fischer) or with API 4000 instrument (SCIEX) equipped with an 
Ionspray/APCI source. When necessary, samples were stored at −20 °C prior to analysis. 
Fluorescence measurements were performed on a Perkin Elmer PE spectrofluorometer with temperature 
control (± 0.1 °C). Calf-thymus DNA (B-double helix, highly polymerized salt) and ethidium bromide (EB) 
were received from Merck. Calf-thymus DNA was sonicated to reduce its length to ca. 500 base pairs.61 The 
concentrations of DNA (CDNA, referred to base pairs; λ = 260 nm, ε = 13200 M
−1 · cm−1),62 EB (CEB;λ = 480 
nm, ε = 5700 M−1 · cm−1)63 and BSA (CBSA; λ = 278 nm, ε = 44000 M
−1 · cm−1) 64 were determined 
spectrophotometrically. The solutions were prepared with ultra-pure water (Sartorius). A sodium cacodylate 
(NaCac) buffer was used to keep pH of solutions at 7.0, whereas NaCl was used to adjust the ionic strength 
close to physiological conditions (0.1 M). For EB/DNA exchange experiments, a stock 1.73·10−4 M solution 
(NaCac 0.01 M, NaCl 0.1 M, pH = 7.0) was used to titrate a 2.14·10−4 M solution of DNA directly into 
the spectrofluorometric cell. Additions of the titrant were carried out with a Gastight syringe connected 
to a Mitutoyo screw (minimum amount = 0.164 µL). The DNA was saturated (and EB addition was 
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stopped) when the fluorescence emission increase faded out (T = 25 °C, CDNA/CEB≅ 2, λexc = 520 nm, 
λem = 530-650 nm, λem
MAX = 595 nm). After DNA saturation, increasing amounts of the analyzed metal 
complex were added to the EB/DNA mixture. Fluorescence changes were measured at the 
excitation/emission wavelength typical and selective for the EB/DNA intercalated complex (λexc = 520 
nm, λem = 595 nm). The blank test was done by adding DMSO only to the EB/DNA mixture, in order to 
quantify fluorescence changes due to solvent and dilution effects. In the case of direct metal 
complex/BSA fluorescence titrations, a similar procedure was used, thus the analyzed metal complex 
(ca. 10-3 M, DMSO solution) was added to 10−6 M BSA solutions (NaCac 0.01 M, NaCl 0.1 M, pH = 
7.0). The volumes of the added solutions of metal complexes are so small to ensure negligible presence 
of DMSO in the system. 
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